O'Byrne Jason has filed 13 insider transactions across 2 companies since February 2024.
Most recent transaction: a transaction of 2500 shares of Vir Biotechnology, Inc. ($VIR) on March 20, 2026.
Activity breakdown: 0 open-market purchases and 3 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 20, 2026 | Vir Biotechnology, Inc. | $VIR | O'Byrne Jason | EVP & Chief Financial Officer | J | Common Stock | 2500 | $0.00 | 162,615.0000 | 139,125,032 | 1.51% | 0.00% |
| March 20, 2026 | Vir Biotechnology, Inc. | $VIR | O'Byrne Jason | EVP & Chief Financial Officer | J | Common Stock | 2500 | $0.00 | 162,615.0000 | 139,125,032 | 1.56% | 0.00% |
| Feb. 24, 2026 | Vir Biotechnology, Inc. | $VIR | O'Byrne Jason | EVP & Chief Financial Officer | S | Common Stock | 1634 | $9.53 | 162,615.0000 | 139,125,032 | 0.99% | 0.00% |
| Feb. 22, 2026 | Vir Biotechnology, Inc. | $VIR | O'Byrne Jason | EVP & Chief Financial Officer | A | Stock Option (Right to Buy) | 110000 | $0.00 | 110,000.0000 | 139,125,032 | 9999.99% | 0.08% |
| Feb. 23, 2026 | Vir Biotechnology, Inc. | $VIR | O'Byrne Jason | EVP & Chief Financial Officer | S | Common Stock | 2089 | $7.45 | 164,249.0000 | 139,125,032 | 1.26% | 0.00% |
| Feb. 22, 2026 | Vir Biotechnology, Inc. | $VIR | O'Byrne Jason | EVP & Chief Financial Officer | A | Common Stock | 55000 | $0.00 | 166,338.0000 | 139,125,032 | 49.40% | 0.04% |
| Nov. 17, 2025 | Vir Biotechnology, Inc. | $VIR | O'Byrne Jason | EVP & Chief Financial Officer | S | Common Stock | 6799 | $5.56 | 110,701.0000 | 139,125,032 | 5.79% | 0.00% |
| Feb. 22, 2025 | Vir Biotechnology, Inc. | $VIR | O'Byrne Jason | EVP & Chief Financial Officer | A | Stock Option (Right to Buy) | 80000 | $0.00 | 80,000.0000 | 137,143,286 | 9999.99% | 0.06% |
| Feb. 22, 2025 | Vir Biotechnology, Inc. | $VIR | O'Byrne Jason | EVP & Chief Financial Officer | A | Common Stock | 40000 | $0.00 | 115,000.0000 | 137,143,286 | 53.33% | 0.03% |
| Nov. 15, 2024 | Vir Biotechnology, Inc. | $VIR | O'Byrne Jason | EVP & Chief Financial Officer | A | Stock Option (Right to Buy) | 150000 | $0.00 | 150,000.0000 | 0 | 9999.99% | 0.00% |
| Nov. 15, 2024 | Vir Biotechnology, Inc. | $VIR | O'Byrne Jason | EVP & Chief Financial Officer | A | Common Stock | 75000 | $0.00 | 75,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 20, 2024 | Caribou Biosciences, Inc. | $CRBU | O'Byrne Jason | Chief Financial Officer | A | Common Stock | 33000 | $0.00 | 59,224.0000 | 0 | 125.84% | 0.00% |
| Feb. 20, 2024 | Caribou Biosciences, Inc. | $CRBU | O'Byrne Jason | Chief Financial Officer | A | Option to purchase Common Stock | 153000 | $0.00 | 153,000.0000 | 0 | 9999.99% | 0.00% |